Immune Checkpoint Inhibitors (ICIs)-Related Cardiotoxicity

Zarifa, Abdulrazzak; Lopez‐Mattei, Juan; Palaskas, Nicolas; Iliescu, Cezar; Durand, Jean Bernard; Kim, Peter Y.

doi:10.1007/978-3-030-41008-7_15

Cited by 9 publications

(6 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As in our patient, myocarditis or inflammation of the myocardial muscle is the most common form of cardiotoxicity caused by ICIs. As mentioned before, it is the most fatal form of cardiotoxicity, with a mortality rate of up to 50% [76][77][78][79][80][81][82][83][84].…”

Section: Discussionmentioning

confidence: 90%

Perimyocarditis Associated with Immune Checkpoint Inhibitors: A Case Report and Review of the Literature

Shalata,

Steckbeck,

Abu Salman

et al. 2024

Medicina

View full text Add to dashboard Cite

Patient prognoses have been significantly enhanced by immune checkpoint inhibitors (ICIs), altering the standard of care in cancer treatment. These novel antibodies have become a mainstay of care for metastatic non-small-cell lung cancer (mNSCLC) patients. Several types of adverse events related to ICIs have been identified and documented as a result of the launch of these innovative medicines. We present here a 74-year-old female patient with a stage IV lung adenocarcinoma, treated with nivolumab plus ipilimumab, who developed perimyocarditis two weeks after receiving the third cycle of immune checkpoint inhibitor therapy. The patient was diagnosed using troponin levels, computed tomography (CT) angiography, and echocardiography. After hospitalization, her cardiac condition was successfully resolved with corticosteroids, colchicine, and symptomatic treatment. To the best of our knowledge, this is one of the rarest cases to be reported of perimyocarditis as a toxicity of immunotherapy in a patient treated for adenocarcinoma of the lung.

show abstract

Section: Discussionmentioning

confidence: 90%

Perimyocarditis Associated with Immune Checkpoint Inhibitors: A Case Report and Review of the Literature

Shalata,

Steckbeck,

Abu Salman

et al. 2024

Medicina

View full text Add to dashboard Cite

show abstract

“…Cardiotoxicity induced by IO therapy refers to a series of cardiac disorders such as myocarditis, pericarditis, arrhythmias, myocardial infarction (MI), etc. [44]. Among these events, myocarditis is associated with the highest morbidity and mortality [45].…”

Section: Cardiac Aesmentioning

confidence: 99%

Complications of immuno‐oncology care: what urologist should know

Grajales,

Martini,

Shore

2024

BJU International

View full text Add to dashboard Cite

ObjectivesTo provide a practical review of immune‐related adverse events (irAEs) that may be encountered in uro‐oncology patients.Patients and MethodsWe conducted a literature review of studies reporting irAEs including articles published through September 2023 for uro‐oncology patients and the potential relevancy for the practicing urologist.ResultsImmunotherapy has revolutionised cancer treatment, extending its impact to urological malignancies including for patients with urothelial, kidney, and prostate cancers. Immuno‐oncology (IO) compounds have achieved measurable and durable responses in these cancers. Urologists, choosing to administer or co‐manage IO patient care, should be prepared to understand, evaluate, and treat irAEs. This review discusses the spectrum of irAEs that can be encountered. Ongoing trials are exploring the use of immunotherapy at earlier stages of uro‐oncological diseases, thus underscoring the evolving landscape of urological cancer treatment. Paradoxically, some data suggests that the occurrence of irAEs is associated with improved oncological outcomes.ConclusionsImmune‐related AEs, while manageable, may be life‐threatening and require lifelong therapy. A thorough understanding of AEs and toxicity of a novel drug class is imperative.

show abstract

“…Therefore, immune checkpoint inhibitors have been used in solid and hematological cancers to enhance the immune system's potential to fight cancer cells ( 114 ). Although existing studies suggest that immune checkpoint inhibitors are less likely to be cardiotoxic, immunotherapy may cause life-threatening events in patients (cardiac arrest, fulminant myocarditis, shock) by disrupting immune homeostasis in the myocardium ( 115 , 116 ).…”

Section: Early-onset and High-incidence Cardiovascular Risks Of Cance...mentioning

confidence: 99%

Cardio-Oncology: A Myriad of Relationships Between Cardiovascular Disease and Cancer

Wang

Han

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Cardiovascular disease (CVD) and cancer are the leading causes of death worldwide. With an increasing number of the elderly population, and early cancer screening and treatment, the number of cancers cases are rising, while the mortality rate is decreasing. However, the number of cancer survivors is increasing yearly. With the prolonged life span of cancer patients, the adverse effects of anti-tumor therapy, especially CVD, have gained enormous attention. The incidence of cardiovascular events such as cardiac injury or cardiovascular toxicity is higher than malignant tumors' recurrence rate. Numerous clinical studies have also shifted their focus from the study of a single disease to the interdisciplinary study of oncology and cardiology. Previous studies have confirmed that anti-tumor therapy can cause CVD. Additionally, the treatment of CVD is also related to the tumors incidence. It is well established that the increased incidence of CVD in cancer patients is probably due to an unmodified unhealthy lifestyle among cancer survivors or cardiotoxicity caused by anti-cancer therapy. Nevertheless, some patients with CVD have a relatively increased cancer risk because CVD and malignant tumors are highly overlapping risk factors, including gender, age, hypertension, diabetes, hyperlipidemia, inflammation, and obesity. With advancements in the diagnosis and treatment, many patients simultaneously suffer from CVD and cancer, and most of them have a poor prognosis. Therefore, clinicians should understand the relationship between CVD and tumors, effectively identify the primary and secondary prevention for these diseases, and follow proper treatment methods.

show abstract

Immune Checkpoint Inhibitors (ICIs)-Related Cardiotoxicity

Cited by 9 publications

References 35 publications

Perimyocarditis Associated with Immune Checkpoint Inhibitors: A Case Report and Review of the Literature

Perimyocarditis Associated with Immune Checkpoint Inhibitors: A Case Report and Review of the Literature

Complications of immuno‐oncology care: what urologist should know

Cardio-Oncology: A Myriad of Relationships Between Cardiovascular Disease and Cancer

Contact Info

Product

Resources

About